

# Meta-analysis: surveillance with ultrasound for early patients with cirrhosis

Alimentary Pharmacology and Therapeutics

30, 37-47

DOI: [10.1111/j.1365-2036.2009.04014.x](https://doi.org/10.1111/j.1365-2036.2009.04014.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma for the non-specialist. <i>BMJ: British Medical Journal</i> , 2009, 339, b5039-b5039.	2.4	21
2	Recent advances in the treatment of hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 189-195.	1.0	79
3	Surveillance for Hepatocellular Carcinoma: Development and Validation of an Algorithm to Classify Tests in Administrative and Laboratory Data. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3241-3251.	1.1	18
4	Screening for hepatocellular carcinoma: Good enough but best yet to come. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 845-846.	1.4	1
5	Current Approaches to the Treatment of Early Hepatocellular Carcinoma. <i>Oncologist</i> , 2010, 15, 34-41.	1.9	50
6	Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. <i>Journal of Hepatology</i> , 2010, 53, 291-297.	1.8	281
7	Care of the Liver Transplant Candidate. <i>Clinics in Liver Disease</i> , 2011, 15, 779-806.	1.0	1
8	Hepatocellular Carcinoma: Screening and Staging. <i>Clinics in Liver Disease</i> , 2011, 15, 323-334.	1.0	46
9	HBV-related HCC, clinical issues and therapy. <i>Digestive and Liver Disease</i> , 2011, 43, S32-S39.	0.4	14
10	Biliary, Pancreatic, and Hepatic Imaging for the General Surgeon. <i>Surgical Clinics of North America</i> , 2011, 91, 59-92.	0.5	5
11	Management of Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 385-391.	2.4	1
13	Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2011, 365, 1118-1127.	13.9	3,427
14	Patient Involvement in Healthcare is Associated With Higher Rates of Surveillance for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 727-732.	1.1	83
15	Knowledge of Hepatocellular Carcinoma Screening Guidelines and Clinical Practices Among Gastroenterologists. <i>Digestive Diseases and Sciences</i> , 2011, 56, 569-577.	1.1	27
16	Imaging diagnosis and staging of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2011, 17, S34-S43.	1.3	42
17	On the mechanism of action of vitamin E for nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011, 53, 1067-1067.	3.6	5
18	Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , 2011, 53, 1067-1068.	3.6	4
19	Genotype 4 hepatitis C virus: Beware of false-negative RNA detection. <i>Hepatology</i> , 2011, 53, 1066-1067.	3.6	9

#	ARTICLE	IF	CITATIONS
20	Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites. Hepatology, 2011, 53, 1068-1069.	3.6	4
21	Activation of the endotoxin/toll-like receptor 4 pathway: The way to go from nonalcoholic steatohepatitis up to hepatocellular carcinoma. Hepatology, 2011, 53, 1069-1069.	3.6	5
22	Is achievement of sustained virologic response an independent predictor or a cofactor for the development of esophageal varices?. Hepatology, 2011, 53, 1070-1071.	3.6	0
23	Necrosis versus apoptosis in acetaminophen-induced hepatotoxicity. Hepatology, 2011, 53, 1070-1070.	3.6	14
24	Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases. Hepatology, 2011, 53, 1060-1061.	3.6	54
25	Treatment of hepatic encephalopathy with rifaximin: More to think about. Hepatology, 2011, 53, 1059-1059.	3.6	1
26	Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology, 2011, 53, 1054-1055.	3.6	31
27	The wide spectrum of hepatic iron overload. Hepatology, 2011, 53, 1057-1058.	3.6	2
28	Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?. Hepatology, 2011, 53, 1055-1056.	3.6	4
29	Inflammation does not always kill hepatocytes during liver damage. Hepatology, 2011, 54, 366-366.	3.6	2
32	Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology, 2011, 53, 1064-1065.	3.6	44
34	Neutralization of lipopolysaccharide effects in liver diseases, the quest for the holy grail. Hepatology, 2011, 54, 376-376.	3.6	3
36	Meta-analysis using individual participant data is the gold standard for diagnostic studies. Hepatology, 2011, 53, 1062-1063.	3.6	3
37	Alpha-fetoprotein in hepatocellular carcinoma surveillance: Wake not the dead. Hepatology, 2011, 54, 376-377.	3.6	10
38	Management of hepatocellular carcinoma: An update. Hepatology, 2011, 53, 1020-1022.	3.6	7,111
39	Are there more factors other than hepatitis B virus DNA level and A1762T/G1764A mutation in liver tissue that also independently predict postoperative survival in hepatocellular carcinoma?. Hepatology, 2011, 54, 378-378.	3.6	1
40	Cystic fibrosis-cirrhosis, portal hypertension, and liver biopsy: Reply. Hepatology, 2011, 53, 1065-1066.	3.6	11
41	Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease. Hepatology, 2011, 54, 377-378.	3.6	8

#	ARTICLE	IF	CITATIONS
43	Risk factors for infection in chronic hepatitis C: A high prevalence of sexual exposure among human immunodeficiency virus-coinfected women. <i>Hepatology</i> , 2011, 54, 379-379.	3.6	2
45	Efforts at making the diagnosis of acute-onset autoimmune hepatitis. <i>Hepatology</i> , 2011, 54, 371-372.	3.6	25
46	Autoimmune acute liver failure. <i>Hepatology</i> , 2011, 54, 372-372.	3.6	8
47	Screening for biliary atresia: Swiss stool color card. <i>Hepatology</i> , 2011, 54, 368-368.	3.6	30
48	Misuse of scoring systems. <i>Hepatology</i> , 2011, 54, 369-370.	3.6	29
49	Occult hepatitis b virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C. <i>Hepatology</i> , 2011, 54, 373-373.	3.6	1
50	Reply:. <i>Hepatology</i> , 2011, 54, 370-371.	3.6	1
51	Reply:. <i>Hepatology</i> , 2011, 54, 372-373.	3.6	5
52	Reply:. <i>Hepatology</i> , 2011, 54, 369-369.	3.6	0
53	Reply:. <i>Hepatology</i> , 2011, 54, 367-368.	3.6	3
54	Reply:. <i>Hepatology</i> , 2011, 54, 373-374.	3.6	0
55	Association between human leukocyte antigen DP gene polymorphisms and chronic hepatitis B in a Chinese population. <i>Hepatology</i> , 2011, 54, 375-375.	3.6	0
56	Reply:. <i>Hepatology</i> , 2011, 54, 375-376.	3.6	0
57	Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. <i>Hepatology</i> , 2011, 54, 1987-1997.	3.6	309
58	Surveillance for hepatocellular carcinoma: in whom and how?. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 5-10.	1.4	111
59	APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. <i>International Journal of Hepatology</i> , 2011, 2011, 1-11.	0.4	71
60	The Impact of CT Follow-Up Interval on Stages of Hepatocellular Carcinomas Detected During the Surveillance of Patients With Liver Cirrhosis. <i>American Journal of Roentgenology</i> , 2012, 199, 816-821.	1.0	6
61	Hepatocellular carcinoma: ESMOâ€ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii41-vii48.	0.6	315

#	ARTICLE	IF	CITATIONS
62	Failure Rates in the Hepatocellular Carcinoma Surveillance Process. <i>Cancer Prevention Research</i> , 2012, 5, 1124-1130.	0.7	175
63	Effectiveness of $\alpha$ -fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 441-444.	1.4	13
64	Epidemiology and Surveillance of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 2-14.	4.2	144
65	New Paradigm for Management of Hepatocellular Carcinoma by Imaging. <i>Liver Cancer</i> , 2012, 1, 94-109.	4.2	35
66	Management of HCC. <i>Journal of Hepatology</i> , 2012, 56, S75-S87.	1.8	509
67	Hepatocellular carcinoma. <i>Lancet, The</i> , 2012, 379, 1245-1255.	6.3	3,897
68	What primary care providers need to know about hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 217-219.	1.0	0
69	Current issues and future trends in surveillance for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 186-189.	1.0	2
72	A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2012, 203, 182-190.	0.9	7
73	The changing scenario of hepatocellular carcinoma over the last two decades in Italy. <i>Journal of Hepatology</i> , 2012, 56, 397-405.	1.8	84
74	Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. <i>Journal of Hepatology</i> , 2012, 56, 1089-1096.	1.8	61
75	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 908-943.	1.8	5,214
76	EASL/EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2012, 48, 599-641.	1.3	406
77	Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1113-1134.	1.9	38
78	Quality Improvement in Gastroenterology Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1305-1314.	2.4	11
79	Screening and Management of Hepatocellular Carcinoma: The Australian Perspective. <i>Current Hepatitis Reports</i> , 2012, 11, 197-205.	0.3	0
80	Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 793-799.	1.1	227
82	Chronic HCV infection: epidemiological and clinical relevance. <i>BMC Infectious Diseases</i> , 2012, 12, S2.	1.3	97

#	ARTICLE	IF	CITATIONS
83	Radiologic Diagnosis of Hepatocellular Carcinoma. , 2012, , 45-66.		0
84	Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. <i>Cancer Imaging</i> , 2012, 12, 530-547.	1.2	142
85	Impact social et psychologique des jeux d'argent en ligne chez les jeunes adultes. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2012, 196, 27-36.	0.0	5
86	Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review. <i>Journal of General Internal Medicine</i> , 2012, 27, 861-867.	1.3	245
87	Hepatocellular Carcinoma in Non-cirrhotic Liver Without Evidence of Iron Overload in a Patient with Primary Hemochromatosis. Review. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 36-39.	0.6	11
89	Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. <i>Journal of Viral Hepatitis</i> , 2012, 19, 594-600.	1.0	41
90	Predictors of Liver Transplant Eligibility for Patients with Hepatocellular Carcinoma in a Safety Net Hospital. <i>Digestive Diseases and Sciences</i> , 2012, 57, 580-586.	1.1	15
91	Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. <i>Systematic Reviews</i> , 2013, 2, 37.	2.5	31
92	Consensus Report of the Fifth International Forum for Liver MRI. <i>American Journal of Roentgenology</i> , 2013, 201, 97-107.	1.0	38
93	Review article: the management of autoimmune hepatitis beyond consensus guidelines. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 343-364.	1.9	50
94	Carcinoma hepatocelular: epidemiologia, biologia, diagnóstico e terapias. <i>Revista Da Associação Médica Brasileira</i> , 2013, 59, 514-524.	0.3	81
95	Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines. <i>Journal of Hepatology</i> , 2013, 59, 814-829.	1.8	178
96	Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?. <i>American Journal of Gastroenterology</i> , 2013, 108, 425-432.	0.2	193
98	Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2013, 108, 1723-1730.	0.2	233
99	Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2161-2181.	1.1	143
100	Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2013, 59, 514-524.	0.1	2
101	Improving Screening for Hepatocellular Carcinoma by Incorporating Data on Levels of Î±-Fetoprotein, Over Time. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 437-440.	2.4	87
102	Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 712-723.	0.4	155

#	ARTICLE	IF	CITATIONS
104	HBV Infection and Hepatocellular Carcinoma. Clinics in Liver Disease, 2013, 17, 375-397.	1.0	34
105	Improving Hepatocellular Carcinoma Screening: Applying Lessons From Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2013, 11, 472-477.	2.4	49
106	Î±-Fetoprotein in Hepatocellular Carcinoma Surveillance: Mend It but Do Not End It. Clinical Gastroenterology and Hepatology, 2013, 11, 441-443.	2.4	28
107	Hepatobiliary Quiz-5 (2013). Journal of Clinical and Experimental Hepatology, 2013, 3, 81-85.	0.4	0
109	Predicting Coverage of Transverse Subcostal Sonography With the Use of Previous Computed Tomography Before a Sonographic Liver Examination. Journal of Ultrasound in Medicine, 2013, 32, 2053-2061.	0.8	5
110	Multidisciplinary Management of Hepatocellular Carcinoma: Where Are We Today?. Seminars in Liver Disease, 2013, 33, S3-S10.	1.8	32
111	Recent advances in the treatment of hepatocellular carcinoma. Current Opinion in Gastroenterology, 2013, 29, 285-292.	1.0	93
112	A Multidisciplinary Approach. Journal of Clinical Gastroenterology, 2013, 47, S27-S29.	1.1	7
113	Epidemiology of Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2013, 47, S2-S6.	1.1	996
114	Surveillance for Hepatocellular Carcinoma: How Can We Do Better?. American Journal of the Medical Sciences, 2013, 346, 308-313.	0.4	9
115	Laparoscopic Ultrasound for Hepatocellular Carcinoma and Colorectal Liver Metastasis. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2013, 23, 135-144.	0.4	19
116	Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World Journal of Gastroenterology, 2013, 19, 6744.	1.4	50
117	Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?. World Journal of Gastroenterology, 2013, 19, 8808.	1.4	72
118	Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography - a randomised study. Alimentary Pharmacology and Therapeutics, 2013, 38, 303-312.	1.9	133
119	Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8900 high-risk patients. Hpb, 2013, 15, 985-990.	0.1	28
120	Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Alimentary Pharmacology and Therapeutics, 2013, 38, 703-712.	1.9	92
122	Lo que los profesionales de atención primaria necesitan saber sobre el carcinoma hepatocelular. Clinical Liver Disease, 2013, 2, S1Á-S3Á.	1.0	0
123	Reply to Giannini and Trevisani. American Journal of Gastroenterology, 2013, 108, 1014.	0.2	0

#	ARTICLE	IF	CITATIONS
124	Hepatocellular Carcinoma Surveillance at 4- vs. 12-Month Intervals for Patients With Chronic Viral Hepatitis: A Randomized Study in Community. <i>American Journal of Gastroenterology</i> , 2013, 108, 416-424.	0.2	61
125	Therapeutic Delays Lead to Worse Survival Among Patients With Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1101-1108.	2.3	69
126	Recent development of diagnostic imaging of hepatocellular carcinoma. <i>Journal of the Korean Medical Association</i> , 2013, 56, 948.	0.1	1
128	Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. <i>Annals of Hepatology</i> , 2013, 12, 766-773.	0.6	31
130	Evaluation of 131I-Anti-Angiotensin II Type 1 Receptor Monoclonal Antibody as a Reporter for Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e85002.	1.1	6
131	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2014, 13, S4-S40.	0.6	34
132	Epidemiology of HCC in Brazil: Incidence and risk factors in a ten-year cohort. <i>Annals of Hepatology</i> , 2014, 13, 386-393.	0.6	47
133	Hepatocellular carcinoma and cholangiocarcinoma: an update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 63-82.	1.4	16
134	A Primer on Effectiveness and Efficacy Trials. <i>Clinical and Translational Gastroenterology</i> , 2014, 5, e45.	1.3	540
135	Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong Renal Registry. <i>Renal Failure</i> , 2014, 36, 865-869.	0.8	7
136	2014 KLCSC-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma: HCC Diagnostic Algorithm. <i>Digestive Diseases</i> , 2014, 32, 764-777.	0.8	60
137	Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001624.	3.9	607
138	Mexican consensus on the diagnosis and management of hepatocellular carcinoma. <i>Revista De Gastroenterología De México (English Edition)</i> , 2014, 79, 250-262.	0.1	3
139	Hepatocellular Carcinoma Screening and Diagnosis. <i>Seminars in Liver Disease</i> , 2014, 34, 389-397.	1.8	15
140	An acute unusual presentation of hepatocellular carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 401.	0.3	2
142	Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. <i>Revista De Gastroenterología De México</i> , 2014, 79, 250-262.	0.4	13
144	Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1699-1705.	1.4	23
145	Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: A systematic review. <i>Hepatology Research</i> , 2014, 44, E11-25.	1.8	62



#	ARTICLE	IF	CITATIONS
146	Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. <i>Digestive Diseases and Sciences</i> , 2014, 59, 3073-3077.	1.1	25
147	Emerging Trends in Hepatocellular Carcinoma: Focus on Diagnosis and Therapeutics. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S9926.	0.6	127
148	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 144-153.	1.1	217
149	Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study. <i>United European Gastroenterology Journal</i> , 2014, 2, 279-287.	1.6	29
150	Surveillance for Hepatocellular Carcinoma: Evidence Guidelines and Utilization. <i>American Journal of the Medical Sciences</i> , 2014, 347, 415-419.	0.4	8
151	Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. <i>World Journal of Hepatology</i> , 2014, 7, 139.	0.8	72
152	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1927-1933.e2.	2.4	108
154	Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma. <i>Tumor Biology</i> , 2014, 35, 2327-2333.	0.8	15
155	Hepatocellular Carcinoma and Other Liver Lesions. <i>Medical Clinics of North America</i> , 2014, 98, 103-118.	1.1	14
156	How grim is hepatocellular carcinoma?. <i>Annals of Medicine and Surgery</i> , 2014, 3, 71-76.	0.5	17
157	Hepatocellular carcinoma tumour markers: Current role and expectations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 843-853.	1.0	89
159	Factors That Affect Accuracy of $\alpha$ -Fetoprotein Test in Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 870-877.	2.4	109
160	Surveillance for Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S50-S56.	0.4	4
161	The Changing Landscape of Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2014, 184, 574-583.	1.9	82
162	The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review. <i>Cancer</i> , 2014, 120, 2824-2838.	2.0	212
163	Role of Surveillance in Prevention of Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S43-S49.	0.4	5
164	Limitations of screening for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014, 1, 161-163.	4.2	7
165	The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S3-S26.	0.4	50

#	ARTICLE	IF	CITATIONS
166	Screening for Hepatocellular Carcinoma in Chronic Liver Disease. <i>Annals of Internal Medicine</i> , 2014, 161, 261.	2.0	183
167	Screening Process Failures for Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 375-382.	2.3	34
168	Preventing hepatocellular carcinoma: the crucial role of chronic hepatitis B monitoring and antiviral treatment. <i>Hepatic Oncology</i> , 2014, 1, 255-257.	4.2	3
169	Ectopic Spleen Tissue - an Underestimated Differential Diagnosis of a Hypervascularised Liver Tumour. <i>Visceral Medicine</i> , 2015, 31, 445-447.	0.5	4
170	The efficacy and effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatic Oncology</i> , 2015, 2, 97-99.	4.2	2
171	Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry. <i>BMC Cancer</i> , 2015, 15, 985.	1.1	21
172	Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?. <i>Liver International</i> , 2015, 35, 1862-1871.	1.9	55
174	2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2015, 16, 465.	1.5	168
175	The Korean guideline for hepatocellular carcinoma surveillance. <i>Journal of the Korean Medical Association</i> , 2015, 58, 385.	0.1	14
176	Hepatocellular carcinoma: From diagnosis to treatment. <i>World Journal of Hepatology</i> , 2015, 7, 1020.	0.8	137
177	Current Role of Contrast-Enhanced Ultrasound in the Diagnosis of Hepatocellular Carcinoma. <i>Journal of Hepatology and Gastrointestinal Disorders</i> , 2015, 01, .	0.0	1
178	Guide for diagnosis and treatment of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1632.	0.8	185
179	Imaging of HCC-Current State of the Art. <i>Diagnostics</i> , 2015, 5, 513-545.	1.3	40
180	Early Detection of Hepatocellular Carcinoma: How to Screen and Follow up Patients with Liver Cirrhosis According to the GERMAN S3 Guideline?. <i>Diagnostics</i> , 2015, 5, 497-503.	1.3	11
181	Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 2-14.	0.3	12
182	The Effectiveness of Ultrasound Surveillance for Hepatocellular Carcinoma in a Canadian Centre and Determinants of Its Success. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 267-273.	0.8	15
183	Hepatocellular Carcinoma: Consensus, Controversies and Future Directions: A Report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 178-184.	0.8	37
184	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 603-627.	1.4	102

#	ARTICLE	IF	CITATIONS
185	Diagnostic Per-Patient Accuracy of an Abbreviated Hepatobiliary Phase Gadoteric Acid-Enhanced MRI for Hepatocellular Carcinoma Surveillance. <i>American Journal of Roentgenology</i> , 2015, 204, 527-535.	1.0	105
186	IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. <i>BMC Gastroenterology</i> , 2015, 15, 50.	0.8	47
187	Clinical guideline SEOM: hepatocellular carcinoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 988-995.	1.2	29
188	Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. <i>Medicine (United States)</i> , 2015, 94, e901.	0.4	16
189	Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance. <i>American Journal of Medicine</i> , 2015, 128, 90.e1-90.e7.	0.6	128
191	Multicenter analysis of soluble $\alpha$ -fetoprotein reveals diagnostic value for very early stage hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 385-394.	2.3	41
192	Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. <i>Medical Oncology</i> , 2015, 32, 432.	1.2	19
193	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. <i>Journal of Hepatology</i> , 2015, 62, 848-854.	1.8	228
194	A new approach to the use of $\alpha$ -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. <i>British Journal of Cancer</i> , 2015, 112, 69-76.	2.9	66
195	Elevated Alpha-Fetoprotein. <i>Clinics in Liver Disease</i> , 2015, 19, 309-323.	1.0	118
196	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. <i>Lancet Oncology</i> , 2015, 16, 804-815.	5.1	237
197	Screening for Hepatocellular Carcinoma and Cholangiocarcinoma: Can Biomarkers Replace Imaging?. <i>Current Hepatology Reports</i> , 2015, 14, 128-138.	0.4	9
198	Hepatocellular carcinoma surveillance with miRNAs. <i>Lancet Oncology</i> , 2015, 16, 743-745.	5.1	31
199	Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands. <i>Journal of Hepatology</i> , 2015, 63, 1156-1163.	1.8	117
200	Imagiological Diagnosis of Gastrointestinal Diseases - Diagnostic Criteria of Hepatocellular Carcinoma. <i>GE Portuguese Journal of Gastroenterology</i> , 2015, 22, 153-160.	0.3	8
201	Trend of Improving Prognosis of Hepatocellular Carcinoma in Clinical Practice: An Italian In-Field Experience. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1465-1473.	1.1	10
202	Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. <i>American Journal of Gastroenterology</i> , 2015, 110, 836-844.	0.2	108
203	2014 KLCSCG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2015, 9, 267-317.	1.4	167

#	ARTICLE	IF	CITATIONS
204	Surveillance for hepatocellular carcinoma in a mixed-aetiology UK cohort with cirrhosis: does $\alpha$ -fetoprotein still have a role?. <i>Clinical Medicine</i> , 2015, 15, 139-144.	0.8	3
205	Incidentally Discovered Hepatocellular Carcinoma in Explanted Liver: Clinical, Histopathologic Features and Outcome. <i>Transplantation Proceedings</i> , 2015, 47, 1051-1054.	0.3	12
206	Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. <i>Hepatology Research</i> , 2015, 45, 415-422.	1.8	7
208	Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. <i>Current Gastroenterology Reports</i> , 2015, 17, 34.	1.1	7
209	Imaging in Patients with Cirrhosis. <i>Radiologic Clinics of North America</i> , 2015, 53, 919-931.	0.9	4
210	Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2140-2151.	2.4	436
211	Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. <i>Biomarkers in Medicine</i> , 2015, 9, 1343-1351.	0.6	18
212	Use of Biomarkers in Screening for Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 867, 27-39.	0.8	45
213	Clinical Reminders for Hepatocellular Carcinoma Surveillance: An Early Step in a Long Journey. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 180-182.	2.4	2
214	Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 791-798.e1.	2.4	86
215	Management of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 861-876.	1.2	92
216	Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 412-420.	0.8	7
217	Improving Outcome in Gastrointestinal and Hepatopancreaticobiliary Surgical Oncology by Preoperative Risk Assessment and Optimization of Perioperative Care. , 2016, , .		1
218	Hepatocellular carcinoma: Where are we?. <i>World Journal of Experimental Medicine</i> , 2016, 6, 21.	0.9	104
219	A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 7-17.	4.5	232
220	Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues. <i>Korean Journal of Radiology</i> , 2016, 17, 7.	1.5	48
221	An Atypical Initial Presentation of Hepatocellular Carcinoma as Spinal Cord Compression. , 2016, 06, .		1
222	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 262.	1.4	96

#	ARTICLE	IF	CITATIONS
223	A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. <i>Frontline Gastroenterology</i> , 2016, 7, 82-89.	0.9	23
224	Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983â€“2012. <i>International Journal of Circumpolar Health</i> , 2016, 75, 31115.	0.5	10
225	The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2016, 54, 1296-1305.	0.2	83
226	Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. <i>Scientific Reports</i> , 2016, 6, 35050.	1.6	16
228	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 875-886.e6.	2.4	217
229	Management of Hepatocellular Carcinoma (HCC). <i>Current Surgery Reports</i> , 2016, 4, 1.	0.4	5
230	Hepatitis B and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2016, 20, 703-720.	1.0	28
232	Screening and surveillance for hepatocellular carcinoma: perspective of a new era?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1291-1302.	1.1	4
233	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina ClÃnica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.1	2
234	Protein Biomarkers in the Management of Hepatocellular Carcinoma: Novel Combinatory Approaches. , 2016, , 331-338.		0
235	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. <i>Exposure and Health</i> , 2016, , 1-22.	2.8	0
236	Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 110-115.	0.5	9
237	Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S70-S76.	0.6	25
238	Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 15447-15456.	0.8	22
239	Surveillance for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 1001-1010.	1.0	25
240	Preparation, characterization and evaluation of <sup>186</sup> Reâ€“idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 72-77.	0.5	20
241	Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). <i>Oncology Reports</i> , 2016, 36, 613-625.	1.2	58
242	Highly sensitive alphaâ€“fetoprotein, <i>Lens culinaris</i> agglutininâ€“reactive fraction of alphaâ€“fetoprotein and desâ€“gammaâ€“carboxyprothrombin for hepatocellular carcinoma detection. <i>Hepatology Research</i> , 2016, 46, E130-5.	1.8	52

#	ARTICLE	IF	CITATIONS
243	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 835-853.	0.6	1,365
244	Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2016, 4, 237-240.	0.6	5
245	Hepatocellular carcinoma: From diagnosis to treatment. <i>Surgical Oncology</i> , 2016, 25, 74-85.	0.8	369
246	Three cases of hepatocellular carcinoma in Fontan patients: Review of the literature and suggestions for hepatic screening. <i>International Journal of Cardiology</i> , 2016, 206, 21-26.	0.8	53
247	Diagnostic criteria for hepatocellular carcinoma $\leq 1/2$ cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. <i>Journal of Hepatology</i> , 2016, 64, 1099-1107.	1.8	93
249	Reply to "Surveillance for hepatocellular carcinoma: A tale of two countries". <i>Journal of Hepatology</i> , 2016, 64, 755-756.	1.8	2
250	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	0.6	68
251	Radiology in Liver Transplantation. , 2017, , 383-426.		0
252	Editorial: ultrasound surveillance of hepatocellular carcinoma in the 21st century - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 562-563.	1.9	1
253	Ultrasound of the liver, biliary tract, and pancreas. , 2017, , 245-275.e4.		2
254	Developing a liver cancer program in the nonacademic medical center. <i>Clinical Liver Disease</i> , 2017, 9, 25-28.	1.0	2
255	Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. <i>American Journal of Medicine</i> , 2017, 130, 1099-1106.e1.	0.6	99
256	Imaging of hepatocellular carcinoma and image guided therapies - how we do it. <i>Cancer Imaging</i> , 2017, 17, 9.	1.2	23
257	Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 277-279.	1.4	20
258	Diagnosis of hepatocellular carcinoma: An update on international guidelines. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 379-391.	1.8	41
259	Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. <i>Journal of Hepatology</i> , 2017, 67, 603-618.	1.8	292
260	Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?. <i>Current Hepatology Reports</i> , 2017, 16, 137-145.	0.4	26
261	Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 650-655.	1.1	35

#	ARTICLE	IF	CITATIONS
262	Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer, 2017, 17, 279.	1.1	13
263	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International, 2017, 11, 317-370.	1.9	1,537
264	Surveillance of the Patients with High Risk of Hepatocellular Cancer. Journal of Gastrointestinal Cancer, 2017, 48, 246-249.	0.6	1
265	Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?. Current Hepatology Reports, 2017, 16, 64-71.	0.4	17
266	Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. Gastroenterology, 2017, 152, 608-615.e4.	0.6	81
267	Liver Disease in Clinical Practice. In Clinical Practice, 2017, , .	0.1	0
268	A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis. Clinical Cancer Research, 2017, 23, 2750-2758.	3.2	31
269	The role of imaging in the surveillance and diagnosis of hepatocellular cancer. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 171-179.	0.9	13
270	Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature Materials, 2017, 16, 1155-1161.	13.3	641
271	Liver investigations: Updating on US technique and contrast-enhanced ultrasound (CEUS). European Journal of Radiology, 2017, 96, 65-73.	1.2	30
272	A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Scientific Reports, 2017, 7, 8954.	1.6	4
273	Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e51-e62.	0.7	39
274	Vitamin D and K signaling pathways in hepatocellular carcinoma. Gene, 2017, 629, 108-116.	1.0	11
275	Contrast-enhanced ultrasound features of hepatocellular carcinoma not detected during the screening procedure. Zeitschrift Fur Gastroenterologie, 2017, 55, 748-753.	0.2	6
276	Biomarker development for hepatocellular carcinoma early detection: current and future perspectives. Hepatic Oncology, 2017, 4, 111-122.	4.2	59
277	Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. BMJ Open, 2017, 7, e015936.	0.8	2
278	Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clinical and Translational Gastroenterology, 2017, 8, e101.	1.3	124
279	PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (United States), 2017, 96, e7266.	0.4	29



#	ARTICLE	IF	CITATIONS
280	Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 169-177.	1.9	243
281	An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 1196-1205.	3.6	188
282	Surveillance of Hepatocellular Carcinoma by Magnetic Resonance Imaging With Liver-Specific Contrast. <i>JAMA Oncology</i> , 2017, 3, 446.	3.4	3
283	MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 456.	3.4	241
284	Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 34-39.	0.9	34
286	ACR Appropriateness Criteria® Chronic Liver Disease. <i>Journal of the American College of Radiology</i> , 2017, 14, S391-S405.	0.9	18
287	Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. <i>Non-coding RNA Research</i> , 2017, 2, 129-136.	2.4	57
289	PRO: Hepatocellular Carcinoma Surveillance: A Useful Tool Against the Rising Tide of HCC. <i>American Journal of Gastroenterology</i> , 2017, 112, 1632-1633.	0.2	3
290	Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. <i>BMC Cancer</i> , 2017, 17, 877.	1.1	30
291	Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis. <i>Annals of Hepatology</i> , 2017, 16, 421-429.	0.6	8
292	Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 285-293.	1.1	13
293	Hepatocellular carcinoma: early-stage management challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 81-92.	1.8	60
294	Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	13
295	Screening for hepatocellular carcinoma: patient selection and perspectives. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 71-79.	1.8	27
296	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2017, 12, e0166188.	1.1	8
297	Reverse lectin ELISA for detecting fucosylated forms of Î±1-acid glycoprotein associated with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0173897.	1.1	19
298	Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 23-27.	1.8	26
299	Surveillance of hepatocellular carcinoma: is only ultrasound enough?. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 222-223.	4.5	8



#	ARTICLE	IF	CITATIONS
300	The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 72-72.	1.5	21
301	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. <i>European Radiology</i> , 2018, 28, 3513-3521.	2.3	24
302	Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1201-1212.	1.9	14
303	Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy. <i>Gastroenterology</i> , 2018, 154, 1848-1850.	0.6	3
304	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
305	Hepatocellular carcinoma surveillance with ultrasound—cost-effectiveness, high-risk populations, uptake. <i>British Journal of Radiology</i> , 2018, 91, 20170436.	1.0	7
306	Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. <i>European Journal of Radiology</i> , 2018, 101, 72-81.	1.2	263
307	Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1706-1718.e1.	0.6	695
308	Incidence and risk factors associated with hepatocellular carcinoma surveillance failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1524-1529.	1.4	18
309	Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. , 2018, , 263-296.		0
310	Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. <i>Clinical Radiology</i> , 2018, 73, 485-493.	0.5	63
311	Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. <i>Cancer Biomarkers</i> , 2018, 21, 603-612.	0.8	24
312	Hepatitis B Virus and Liver Disease. , 2018, , .		1
314	Locoregional Therapies for Hepatocellular Carcinoma. <i>Molecular Pathology Library</i> , 2018, , 213-233.	0.1	0
315	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018, 391, 1301-1314.	6.3	3,878
316	Individual State Hepatitis C Data Supports Expanding Screening Beyond Baby Boomers to All Adults. <i>Gastroenterology</i> , 2018, 154, 1850-1851.e2.	0.6	33
317	Diagnostic accuracy of <sc>SCCA</sc> and <sc>SCCA</sc>+α-fetoprotein for hepatocellular carcinoma: A meta-analysis. <i>Liver International</i> , 2018, 38, 1820-1831.	1.9	18
318	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 381-403.	0.8	92

#	ARTICLE	IF	CITATIONS
319	Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. <i>Journal of Hepatology</i> , 2018, 68, 526-549.	1.8	506
320	Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 476-480.	0.6	13
321	Hepatocellular Carcinoma Risk After Hepatitis C Cure. Current Treatment Options in Infectious Diseases, 2018, 10, 330-336.	0.8	0
322	Hepatocellular Carcinoma Surveillance: Benefit of Serum Alfa-fetoprotein in Real-world Practice. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2018, 8, 83-87.	0.1	19
323	Misconceptions Surrounding Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2018, 12, 154-159.	1.0	0
324	Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-6.	0.7	154
325	The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. <i>Current Hepatology Reports</i> , 2018, 17, 324-335.	0.4	8
326	Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. <i>BMC Cancer</i> , 2018, 18, 915.	1.1	31
327	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv238-iv255.	0.6	663
328	Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. <i>Gastroenterology</i> , 2018, 155, 1436-1450.e6.	0.6	183
329	Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. <i>World Journal of Gastroenterology</i> , 2018, 24, 2348-2362.	1.4	109
330	LI-RADS v2018: a Primer and Update for Clinicians. <i>Current Hepatology Reports</i> , 2018, 17, 425-433.	0.4	0
331	Reply. <i>Gastroenterology</i> , 2018, 155, 1275-1276.	0.6	0
332	Surveillance for Early-Stage Hepatocellular Carcinoma by Ultrasound Plus Alpha-Fetoprotein Measurement: More Details, More Significance. <i>Gastroenterology</i> , 2018, 155, 1274-1275.	0.6	3
333	Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2018, 24, 1171-1177.	1.3	47
334	Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 8396-8404.	0.8	13
335	The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. <i>Korean Journal of Radiology</i> , 2018, 19, 568.	1.5	33
336	Hepatobiliary Cancer. , 2018, , 127-147.		0

#	ARTICLE	IF	CITATIONS
337	Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 585-602.	1.0	20
339	Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. <i>Cancer Biomarkers</i> , 2018, 23, 235-242.	0.8	19
340	Optimal <i>M</i>-Switch Surveillance Policies for Liver Cancer in a Hepatitis C-Infected Population. <i>Operations Research</i> , 2018, 66, 673-696.	1.2	18
341	Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0196081.	1.1	12
342	Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. <i>Molecular and Translational Medicine</i> , 2019, , 3-25.	0.4	6
343	The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986191.	1.4	23
344	Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN). <i>Radiology</i> , 2019, 292, 638-646.	3.6	30
345	Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 2195-2205.	6.1	180
346	ACR Ultrasound Liver Reporting and Data System: Multicenter Assessment of Clinical Performance at One Year. <i>Journal of the American College of Radiology</i> , 2019, 16, 1656-1662.	0.9	25
347	Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. <i>Radiology</i> , 2019, 292, 390-397.	3.6	41
348	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290.	0.6	13
349	VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2019, 19, 167.	0.8	20
350	CNN-Based Macropixel-Level Up-Sampling for Plenoptic Image Coding. <i>IEEE Access</i> , 2019, 7, 80020-80026.	2.6	1
351	Efficient scheduling for multi-stage coflows. <i>CCF Transactions on Networking</i> , 2019, 2, 83-97.	1.0	1
352	A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B. <i>Clinical Chemistry</i> , 2019, 65, 1543-1553.	1.5	53
353	Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 838-839.	1.9	0
354	MRI assessment of hepatocellular carcinoma after locoregional therapy. <i>Insights Into Imaging</i> , 2019, 10, 8.	1.6	22
355	Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. <i>PLoS ONE</i> , 2019, 14, e0221614.	1.1	6

#	ARTICLE	IF	CITATIONS
356	A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 302-310.	1.2	58
357	Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy. Scandinavian Journal of Gastroenterology, 2019, 54, 1132-1137.	0.6	6
358	Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. Journal of Clinical and Experimental Hepatology, 2019, 9, 625-651.	0.4	8
359	Multiparametric ultrasound in liver diseases: an overview for the practising clinician. Postgraduate Medical Journal, 2019, 95, 425-432.	0.9	19
360	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 23-30.	1.8	16
361	Regression discontinuity analysis of alpha-fetoprotein with a cutoff of 20 ng/mL in hepatocellular carcinoma surveillance for chronic hepatitis B. GastroHep, 2019, 1, 70-75.	0.3	0
362	Acidic pH-Activated Gas-Generating Nanoparticles with Pullulan Decorating for Hepatoma-Targeted Ultrasound Imaging. ACS Applied Materials & Interfaces, 2019, 11, 22194-22205.	4.0	31
363	Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. Korean Journal of Radiology, 2019, 20, 863.	1.5	23
364	Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 7704.	1.6	82
365	Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000. Journal of Clinical Laboratory Analysis, 2019, 33, e22921.	0.9	9
366	Role of US LI-RADS in the LI-RADS Algorithm. Radiographics, 2019, 39, 690-708.	1.4	45
367	Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study. World Journal of Surgical Oncology, 2019, 17, 75.	0.8	11
368	Abbreviated MRI Protocols for the Abdomen. Radiographics, 2019, 39, 744-758.	1.4	73
369	Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2019, 17, 1840-1849.e16.	2.4	82
370	Ultrasound Screening and Surveillance in Hepatocellular Carcinoma. Current Radiology Reports, 2019, 7, 1.	0.4	0
371	Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection. Seminars in Liver Disease, 2019, 39, 163-177.	1.8	45
372	Dynamic Computed Tomography Perfusion Imaging: Complementary Diagnostic Tool in Hepatocellular Carcinoma Assessment From Diagnosis to Treatment Follow-up. Academic Radiology, 2019, 26, 1675-1685.	1.3	12
373	Dynamic edge-based biomarker non-invasively predicts hepatocellular carcinoma with hepatitis B virus infection for individual patients based on blood testing. Journal of Molecular Cell Biology, 2019, 11, 665-677.	1.5	17

#	ARTICLE	IF	CITATIONS
374	Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. Radiologic Clinics of North America, 2019, 57, 563-583.	0.9	7
376	Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 864.	1.8	40
377	HCC in Cirrhotic and Non-cirrhotic Liver: Timing to Surgery and Outcome - State of the Art. , 0, , .		0
378	Quantitative Ultrasound Spectroscopy for Differentiation of Hepatocellular Carcinoma from At-Risk and Normal Liver Parenchyma. Clinical Cancer Research, 2019, 25, 6683-6691.	3.2	8
381	Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. The Cochrane Library, 0, , .	1.5	3
382	Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience. Radiology Imaging Cancer, 2019, 1, e190010.	0.7	31
383	Surveillance of hepatocellular carcinoma by medical imaging. Quantitative Imaging in Medicine and Surgery, 2019, 9, 1904-1910.	1.1	9
384	&lt;p&gt;Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort&lt;p&gt;. Cancer Management and Research, 2019, Volume 11, 9379-9386.	0.9	4
385	Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. Aids, 2019, 33, 269-278.	1.0	11
386	Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. Hepatology, 2019, 69, 1180-1192.	3.6	138
387	Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. Liver Transplantation, 2019, 25, 369-379.	1.3	40
388	C3HeB/FeJ Mice mimic many aspects of gene expression and pathobiological features of human hepatocellular carcinoma. Molecular Carcinogenesis, 2019, 58, 309-320.	1.3	2
389	Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. Molecular Genetics and Metabolism, 2019, 128, 236-241.	0.5	32
390	Association of advanced hepatic fibrosis and sonographic visualization score: a dual-center study using ACR US LI-RADS. Abdominal Radiology, 2019, 44, 1415-1422.	1.0	14
391	Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?. Digestive Diseases and Sciences, 2019, 64, 718-728.	1.1	8
392	Statistical methods for detecting outlying and influential studies in meta-analysis of diagnostic test accuracy studies. Statistical Methods in Medical Research, 2020, 29, 1227-1242.	0.7	8
393	Abbreviatedâ€protocol screening MRI vs. completeâ€protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LIâ€RADS v2018. Journal of Magnetic Resonance Imaging, 2020, 51, 415-425.	1.9	57
395	Heterogeneity of Hepatocellular Carcinoma on Imaging. Seminars in Liver Disease, 2020, 40, 061-069.	1.8	12

#	ARTICLE	IF	CITATIONS
396	Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. <i>European Radiology</i> , 2020, 30, 2302-2311.	2.3	19
397	Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. <i>Journal of Hepatology</i> , 2020, 72, 718-724.	1.8	86
398	Screening and Early Detection. , 2020, , 375-398.e7.		1
399	The visualisation of focal liver lesions on ultrasound: A review of 300 liver ultrasounds with CT or MRI correlation. <i>Sonography</i> , 2020, 7, 7-12.	0.4	3
400	Integrin $\alpha 6$ -Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice. <i>Molecular Imaging and Biology</i> , 2020, 22, 864-872.	1.3	8
401	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2020, 72, 671-722.	3.6	473
402	Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRIâ€œCEUS) in Oncology. <i>Cancers</i> , 2020, 12, 2821.	1.7	14
403	Advances in the early diagnosis of hepatocellular carcinoma. <i>Genes and Diseases</i> , 2020, 7, 308-319.	1.5	189
404	The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. <i>BMC Gastroenterology</i> , 2020, 20, 215.	0.8	18
405	OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. <i>Journal of Medical Virology</i> , 2020, 92, 3596-3603.	2.5	28
406	Hepatocellular carcinoma surveillance in Australia: time to improve the diagnosis of cirrhosis and use liver ultrasound. <i>Medical Journal of Australia</i> , 2020, 213, 431.	0.8	1
407	Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. <i>Academic Radiology</i> , 2021, 28, 1464-1476.	1.3	11
408	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020, 10, 579.	1.3	21
409	A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. <i>Liver Cancer</i> , 2020, 9, 503-517.	4.2	40
410	Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0238078.	1.1	1
411	Chronic hepatitis B in children, report of a singleâ€œentre longitudinal study on 152 children. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1344-1351.	1.0	4
412	Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. <i>BMC Gastroenterology</i> , 2020, 20, 251.	0.8	9
413	Imaging Accuracy in Diagnosis of Different Focal Liver Lesions: A Retrospective Study in North of Iran. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 970-975.	0.6	1



#	ARTICLE	IF	CITATIONS
414	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2020, 120, 1581-1590.	0.8	4
415	Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. <i>Radiographics</i> , 2020, 40, 1916-1931.	1.4	43
416	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020, 12, 3218.	1.7	27
417	Baseline assessment of and linkage to care for newly diagnosed patients with chronic hepatitis B. <i>Canadian Liver Journal</i> , 2020, 3, 263-275.	0.3	1
418	Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. <i>Gut</i> , 2020, 69, 1907-1912.	6.1	14
419	Serum small extracellular vesicle-derived <i>LINC00853</i> as a novel diagnostic marker for early hepatocellular carcinoma. <i>Molecular Oncology</i> , 2020, 14, 2646-2659.	2.1	45
420	Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. <i>Journal of International Medical Research</i> , 2020, 48, 030006052093015.	0.4	15
421	Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. <i>Cells</i> , 2020, 9, 1370.	1.8	256
422	Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data. <i>Frontiers in Oncology</i> , 2020, 10, 680.	1.3	106
423	Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoteric acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. <i>European Radiology</i> , 2020, 30, 4150-4163.	2.3	32
424	Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2020, 19, 546-569.	0.6	11
425	Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2020, 29, 189-196.	0.8	17
426	Hepatocellular carcinoma surveillance in Australia: time to improve the diagnosis of cirrhosis and use liver ultrasound. <i>Medical Journal of Australia</i> , 2020, 212, 297.	0.8	5
427	NAFLD and NASH. , 2020, , .		1
428	CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN $\beta$ -THALASSEMIA: PAST, PRESENT AND FUTURE PERSPECTIVES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020006.	0.5	18
429	Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. <i>Current HIV/AIDS Reports</i> , 2020, 17, 6-17.	1.1	7
430	Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis. <i>European Radiology</i> , 2020, 30, 2871-2880.	2.3	23
431	Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 45-76.	1.8	60

#	ARTICLE	IF	CITATIONS
432	Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues. <i>Journal of Hepatology</i> , 2020, 73, 212.	1.8	0
433	Reply to: "Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues". <i>Journal of Hepatology</i> , 2020, 73, 213-214.	1.8	0
434	A blood-based 22-gene expression signature for hepatocellular carcinoma identification. <i>Annals of Translational Medicine</i> , 2020, 8, 195-195.	0.7	5
435	Long Noncoding RNA RMRP Suppresses the Tumorigenesis of Hepatocellular Carcinoma Through Targeting microRNA-766. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3013-3024.	1.0	7
436	Novel Prognostic Scores Based on Plasma Prothrombin Time and Fibrinogen Levels in Patients With AFP-Negative Hepatocellular Carcinoma. <i>Cancer Control</i> , 2020, 27, 107327482091552.	0.7	10
437	Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens. <i>BMC Gastroenterology</i> , 2020, 20, 93.	0.8	5
438	The diagnostic value of contrast-enhanced ultrasound (CEUS) for assessing hepatocellular carcinoma compared to histopathology; a retrospective single-center analysis of 119 patients. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 76, 453-458.	0.9	12
439	Pharmacotherapy options for managing hepatitis B in children. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 449-467.	0.9	3
440	Prognostic role of spleen volume measurement using computed tomography in patients with compensated chronic liver disease from hepatitis B viral infection. <i>European Radiology</i> , 2021, 31, 1432-1442.	2.3	13
441	How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?. <i>Abdominal Radiology</i> , 2021, 46, 969-978.	1.0	5
442	Recent Updates of Abbreviated MRI for Hepatocellular Carcinoma Screening. <i>Journal of the Korean Society of Radiology</i> , 2021, 82, 280.	0.1	0
443	Current status of image-based surveillance in hepatocellular carcinoma. <i>Ultrasonography</i> , 2021, 40, 45-56.	1.0	15
444	Diagnostic Performance of Simulated Abbreviated MRI for Early-Stage Hepatocellular Carcinoma Screening: A Comparison to Conventional Dynamic Contrast-Enhanced MRI. <i>Journal of the Korean Society of Radiology</i> , 2021, 82, 1218.	0.1	0
445	Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. <i>Cancers</i> , 2021, 13, 521.	1.7	5
446	Liver Diseases. , 2021, , 463-492.		1
447	Updates on the Diagnosis and Management of Hepatocellular Carcinoma. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2021, 11, 32-40.	0.1	10
448	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 274-280.	0.6	0
449	Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 790.	1.7	14



#	ARTICLE	IF	CITATIONS
450	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	1.7	9
451	Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C. <i>Sovremennye Tehnologii V Medicine</i> , 2021, 13, 27.	0.4	7
452	Hepatocellular Carcinoma in India. <i>Indian Journal of Surgery</i> , 0, , 1.	0.2	6
453	Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?. <i>Journal of Clinical Medicine</i> , 2021, 10, 903.	1.0	9
454	Translational Perspective in Hepatocellular Carcinoma. , 0, , .		0
455	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	1.3	4
457	Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. , 0, , 55-76.		2
458	Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 653846.	1.3	2
459	Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 1885-1895.	0.2	14
460	Congenital heart disease-associated liver disease: a narrative review. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 577-590.	0.7	4
461	Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2021, 2021, CD013346.	1.5	24
462	The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 418.	1.1	13
463	CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017 – Can Things Be Put Together?. <i>Biology</i> , 2021, 10, 412.	1.3	12
464	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. <i>Cancers</i> , 2021, 13, 2274.	1.7	21
465	Preoperative Alpha-Fetoprotein Has No Prognostic Role in Small Hepatocellular Carcinoma in Non-Cirrhotic Patients After Surgical Resection. <i>Turkish Journal of Gastroenterology</i> , 2021, 32, 133-140.	0.4	0
466	Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies. <i>Oncology and Therapy</i> , 2021, 9, 273-295.	1.0	2
468	Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 2305.	1.7	24
469	Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center. <i>Abdominal Radiology</i> , 2021, 46, 4170-4177.	1.0	3

#	ARTICLE	IF	CITATIONS
470	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
471	Interobserver Agreement Between Primary Sonographers and Secondary Overreaders for Screening and Surveillance Liver Ultrasounds Using Ultrasound Liver Imaging Reporting and Data System. <i>Ultrasound Quarterly</i> , 2022, 38, 116-123.	0.3	3
472	CBCT-guided TACE-MWA for HCC Measuring up to 5 cm. <i>Academic Radiology</i> , 2021, 28, S71-S72.	1.3	1
473	Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. <i>Frontiers in Microbiology</i> , 2021, 12, 665201.	1.5	10
475	Novel non-protein biomarkers for early detection of hepatocellular carcinoma. <i>Engineering</i> , 2021, 7, 1369-1369.	3.2	1
476	Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 108-119.	1.8	83
477	A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. <i>Cancers</i> , 2021, 13, 3977.	1.7	8
478	Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2021, 29, 321-327.	0.6	4
480	Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. <i>Hepatology Communications</i> , 2021, 5, 1972-1986.	2.0	24
481	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.4	4
482	Clinicopathological assessment of steatohepatic hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101799.	0.7	6
483	Exploration and time-serial validation of logistic regression models composed of multiple laboratory tests for early detection of HCV-associated hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2021, 521, 137-143.	0.5	1
484	Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma. <i>Value in Health</i> , 2021, 24, 1454-1462.	0.1	9
485	Controversies in the Management of Hepatitis B. <i>Clinics in Liver Disease</i> , 2021, 25, 785-803.	1.0	4
486	Characteristics and outcome of incidental hepatocellular carcinoma after liver transplantation: a cohort study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.1	1
487	Management of Chronic Hepatitis B Virus Infection in Children and Pregnant Women. , 2021, , 375-410.		0
488	Hepatocellular Carcinoma Surveillance and Staging. <i>Molecular and Translational Medicine</i> , 2019, , 27-51.	0.4	5
490	ACR Appropriateness Criteria Â® Chronic LiverÂDisease. <i>Journal of the American College of Radiology</i> , 2017, 14, S103-S117.	0.9	20

#	ARTICLE	IF	CITATIONS
491	Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. <i>Medical Ultrasonography</i> , 2014, 16, 139-144.	0.4	12
492	Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2020, 51, .	0.3	11
493	S100A14 protein as diagnostic and prognostic marker in hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2019, 9, .	0.3	6
494	Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Medical Science Monitor</i> , 2020, 26, e927444.	0.5	6
495	MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: A systematic review and meta-analysis. <i>Pakistan Journal of Medical Sciences</i> , 2019, 35, 1466-1471.	0.3	22
496	Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. <i>World Journal of Clinical Cases</i> , 2019, 7, 2269-22286.	0.3	21
497	Establishment and Characterization of 7 Novel Hepatocellular Carcinoma Cell Lines from Patient-Derived Tumor Xenografts. <i>PLoS ONE</i> , 2014, 9, e85308.	1.1	32
498	Potential Role of Circulating microRNA-21 for Hepatocellular Carcinoma Diagnosis: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0130677.	1.1	39
499	Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0138907.	1.1	22
500	Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection. <i>PLoS ONE</i> , 2016, 11, e0156801.	1.1	29
501	Hepatocellular carcinoma surveillance: Eastern and Western perspectives. <i>Ultrasonography</i> , 2019, 38, 191-199.	1.0	13
502	Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits. <i>Ultrasonography</i> , 2019, 38, 311-320.	1.0	17
503	Surveillance of Hepatocellular Carcinoma in Cirrhotic Patients: Current Knowledge and Future Directions. <i>Hepatology Forum</i> , 2020, , .	0.3	2
504	Perihepatic lymphadenectomy in children with chronic viral hepatitis. , 2015, 61, 137-150.		10
505	BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. <i>Arquivos De Gastroenterologia</i> , 2020, 57, 1-20.	0.3	22
506	Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance. <i>Journal of Liver Cancer</i> , 2020, 20, 25-31.	0.3	5
507	Hepatocellular Carcinoma in Oman: An analysis of 284 cases. <i>Sultan Qaboos University Medical Journal</i> , 2020, 20, 316.	0.3	3
508	Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. <i>Oncotarget</i> , 2017, 8, 14192-14220.	0.8	60

#	ARTICLE	IF	CITATIONS
509	A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. <i>Oncotarget</i> , 2017, 8, 8775-8784.	0.8	74
510	PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy. <i>Oncotarget</i> , 2017, 8, 29202-29219.	0.8	9
511	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. <i>Oncotarget</i> , 2017, 8, 46234-46248.	0.8	49
512	Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 106499-106510.	0.8	5
513	Alcohol and hepatitis virus-dysregulated lncRNAs as potential biomarkers for hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 224-235.	0.8	14
514	Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. <i>Hepatoma Research</i> , 2020, 2020, .	0.6	10
515	Molecular evaluation of Hepatocyte Growth Factor (HGF) as a potential Biomarker to detect Hepatocellular Carcinoma. <i>Research Journal of Applied Biotechnology</i> , 2017, 3, 1-10.	0.1	1
516	Alternative Biomarkers to Predict Tumor Biology in Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2020, 40, 6573-6784.	0.5	7
517	The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. <i>Clinical Hemorheology and Microcirculation</i> , 2020, 76, 155-160.	0.9	12
518	2018 Korean Liver Cancer Association National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2019, 20, 1042.	1.5	189
519	Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world?. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 239-248.	4.5	38
520	Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 245-263.	4.5	154
521	Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 54-59.	4.5	52
522	Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. <i>World Journal of Gastroenterology</i> , 2013, 19, 7316.	1.4	36
523	Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. <i>World Journal of Gastroenterology</i> , 2014, 20, 11595.	1.4	42
524	Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. <i>World Journal of Gastroenterology</i> , 2016, 22, 7806.	1.4	13
525	Hepatocellular carcinoma surveillance: An evidence-based approach. <i>World Journal of Gastroenterology</i> , 2019, 25, 1550-1559.	1.4	144
526	Management of hepatocellular carcinoma: Enlightening the gray zones. <i>World Journal of Hepatology</i> , 2013, 5, 302.	0.8	38

#	ARTICLE	IF	CITATIONS
527	Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. <i>World Journal of Hepatology</i> , 2015, 7, 2913.	0.8	4
528	Diagnosis and treatment of hepatocellular carcinoma: An update. <i>World Journal of Hepatology</i> , 2015, 7, 362.	0.8	103
529	Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. <i>World Journal of Hepatology</i> , 2015, 7, 1157.	0.8	71
530	Metabonomic window into hepatitis B virus-related hepatic diseases. <i>World Journal of Hepatology</i> , 2016, 8, 1.	0.8	3
531	Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2016, 8, 881.	0.8	29
532	Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. <i>World Journal of Radiology</i> , 2014, 6, 7.	0.5	55
533	Current Limitations and Potential Breakthroughs for the Early Diagnosis of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2011, 5, 15-21.	1.4	33
534	Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2014, 8, 177-185.	1.4	40
535	2018 Korean Liver Cancer Association National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2019, 13, 227-299.	1.4	255
536	Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines. <i>Annals of Saudi Medicine</i> , 2012, 32, 174-199.	0.5	26
537	Predictive role BLVRA mRNA expression in hepatocellular cancer. <i>Annals of Hepatology</i> , 2016, 15, 881-887.	0.6	6
538	Diagnostic and Prognostic Roles of Serum Osteopontin and Osteopontin Promoter Polymorphisms in Hepatitis B-related Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 7211-7217.	0.5	15
539	Current Trends and Recent Advances in Diagnosis, Therapy, and Prevention of Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3595-3604.	0.5	77
540	Diagnosis and Evaluation of Hepatocellular Carcinoma. , 2021, , 1-22.		0
541	Occult Regions of Suppressed Coherence in Liver B-Mode Images. <i>Ultrasound in Medicine and Biology</i> , 2022, 48, 47-58.	0.7	2
543	Facteur de risque et d'apistage du carcinome h'epatocellulaire. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2012, 196, 85-96.	0.0	0
544	Noninvasive diagnosis of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2012, 18, 245.	4.5	0
545	Surveillance for Hepatocellular Carcinoma. , 2012, , 17-43.		0

#	ARTICLE	IF	CITATIONS
546	The Korean National Liver Cancer Surveillance Program: Experience of a Single Healthcare Center in 2011. Korean Journal of Medicine, 2013, 84, 672.	0.1	4
547	Modern radiological diagnosis of hepatocellular carcinoma. Scripta Scientifica Medica, 2014, 45, 7.	0.1	0
548	Cancer Prevention, Screening, and Early Detection. , 2014, , 322-359.e12.		1
549	Radiology in Liver Transplantation. , 2015, , 1-45.		0
550	Radiology in Liver Transplantation. , 2015, , 1-45.		0
552	What Is the Best Way to Screen Cirrhotic Patients for Hepatocellular Carcinoma in the United States?. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 93-111.	0.0	0
553	Radiology in Liver Transplantation. , 2016, , 1-45.		0
554	Serum Alpha-Fetoprotein as a Biomarker in Liver Transplantation. Exposure and Health, 2016, , 1-34.	2.8	2
555	Diagnosis and Management of Hepatocellular Carcinoma. In Clinical Practice, 2017, , 285-306.	0.1	0
556	Primary Liver Cancer: Background and Clinical Evidence. , 2017, , 103-117.		0
557	Serum Alpha-Fetoprotein as a Biomarker in Liver Transplantation. Biomarkers in Disease, 2017, , 837-870.	0.0	1
558	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. Biomarkers in Disease, 2017, , 559-580.	0.0	0
559	Biomarkers for Hepatocellular Carcinoma in East Asia. Biomarkers in Disease, 2017, , 901-925.	0.0	0
560	Lebertumoren. , 2018, , 397-441.		0
563	MOLECULAR EVALUATION OF MIDIKINE (MDK) AS A POTENTIAL BIOMARKER TO DETECT HEPATOCELLULAR CARCINOMA. Research Journal of Applied Biotechnology, 2018, 4, 66-76.	0.1	0
564	Đ;Đ°ÑЄĐ,Đ1/2Ñ–Đ1/2Đ³ Ñ– ÑЄĐ°Đ1/2Đ1/2Ñ•ĐÑ–Đ°Đ³Đ1/2Đ3/4ÑÑ,Đ,Đ°Đ° Đ³ĐμĐ;Đ°Ñ,Đ3/4Ñ†ĐμĐ»ÑŽĐ»ÑÑЄĐ1/2Đ3/4Ñ1– Đ°Đ°ÑЄÑ†Đ,Đ		0
566	Screening for Gastrointestinal Cancers. , 2019, , 573-593.		0
568	Discrepancy between the Actual Clinical Status of Patients with Hepatocellular Carcinoma and Expectations from Hepatocellular Carcinoma Surveillance: a Single-Center Study. Journal of Liver Cancer, 2019, 19, 30-37.	0.3	2

#	ARTICLE	IF	CITATIONS
569	Association of serum growth differentiation factor 15 and hepatocellular carcinoma in Egyptian patients. <i>The Egyptian Journal of Internal Medicine</i> , 2019, 31, 57-63.	0.3	0
570	The Management of Hepatocellular Carcinoma. , 2020, , 237-271.		1
571	Rizikov's factory a surveillance hepatocelulárního karcinomu. <i>Vnitřní Lekarství</i> , 2019, 65, 583-587.	0.1	0
573	Roles of Tumor Markers in Diagnosis and Treatment of Hepatocellular Carcinoma. <i>Korean Journal of Medicine</i> , 2020, 95, 31-35.	0.1	0
574	The Diagnostic role of Soluble (sAxI) Level in Patients with Hepatocellular Carcinoma compared to Alpha-fetoprotein. <i>Afro-Egyptian Journal of Infectious and Endemic Diseases</i> , 2020, 10, 213-225.	0.1	2
575	Evaluation of non-contrast magnetic resonance imaging as an imaging surveillance tool for hepatocellular carcinoma in at-risk patients. <i>Singapore Medical Journal</i> , 2020, , .	0.3	0
576	Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e27470.	0.4	1
577	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. <i>International Immunopharmacology</i> , 2021, 101, 108322.	1.7	18
578	Optimal Modalities for HCC Surveillance in a High Incidence Region. <i>Clinical Liver Disease</i> , 2020, 16, 236-239.	1.0	2
579	Prevention of hepatocellular carcinoma and surveillance of high risk patients. <i>Hepatology Forum</i> , 2021, , .	0.3	5
580	ERKRANKUNGEN DER VERDAUUNGSORGANE. , 2020, , pA-1-pA7.8-14.		0
581	Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2020, 26, 1.	0.5	13
582	Liver Cancer. , 2020, , 341-368.		0
583	HCC in Patients with NAFLD/NASH. , 2020, , 191-203.		0
584	Imaging Modalities for Hepatocellular Carcinoma Surveillance: Expanding Horizons beyond Ultrasound. <i>Journal of Liver Cancer</i> , 2020, 20, 99-105.	0.3	1
585	Liver transplantation for hepatocellular carcinoma: past, present and future. <i>Middle East Journal of Digestive Diseases</i> , 2013, 5, 181-92.	0.2	5
586	Effects of statins on the risk of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2014, 10, 417-26.	0.2	16
589	Surveillance and Diagnosis of Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2015, 11, 38-46.	0.2	11



#	ARTICLE	IF	CITATIONS
590	Surveillance for Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2014, 10, 745-747.	0.2	0
593	Strategies to Improve Hepatocellular Carcinoma Surveillance in Veterans With Hepatitis B Infection. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2017, 34, S30-S39.	0.6	0
594	MicroRNAs as Diagnostic Tools in Hepatocellular Carcinoma. <i>Gastrointestinal Disorders</i> , 2021, 3, 237-246.	0.4	1
596	Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 726213.	1.3	18
597	Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. <i>Liver International</i> , 2022, 42, 2080-2092.	1.9	28
598	Surveillance Strategies for Hepatocellular Carcinoma: Recent Advances and the Shifting Paradigm. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 1336-1339.	0.6	0
599	CURRENT UPDATES ON DIAGNOSTIC BIOMARKERS OF HEPATOCELLULAR CARCINOMA. <i>Indian Drugs</i> , 2019, 56, 7-23.	0.1	0
600	Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. <i>Cancers</i> , 2022, 14, 621.	1.7	34
601	Hepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment. <i>Annals of Surgical Treatment and Research</i> , 2022, 102, 55.	0.4	2
602	Accuracy of Non-Contrast MRI for the Detection of Hepatocellular Carcinoma: A systematic review and meta-analysis. <i>Pakistan Journal of Medical Sciences</i> , 2022, 38, 743-750.	0.3	0
603	An assessment of liver lesions using a combination of CEUS LI-RADS and AFP. <i>Abdominal Radiology</i> , 2022, 47, 1311-1320.	1.0	7
604	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. <i>Journal of Hepatology</i> , 2022, 77, 55-62.	1.8	19
606	Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 371-381.	1.1	6
607	Eliciting Patient Preferences for Hepatocellular Carcinoma Screening: A Choice-Based Conjoint Analysis. <i>Journal of the American College of Radiology</i> , 2022, 19, 502-512.	0.9	3
608	A systematic review and meta-analysis: the diagnostic accuracy of methylated <i>SEPTIN9</i> for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 473-480.	0.6	2
609	Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance. <i>Korean Journal of Radiology</i> , 2022, 23, 598.	1.5	6
610	The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. <i>Revista De Gastroenterología De México (English Edition)</i> , 2022, , .	0.1	1
611	Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 2128.	1.0	6



#	ARTICLE	IF	CITATIONS
612	Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers. <i>Analytical Chemistry</i> , 2022, 94, 6548-6556.	3.2	6
613	Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 2085-2092.	0.8	5
614	Multi-modal imaging for uptake of peptide ligand specific for CD44 by hepatocellular carcinoma. <i>Photoacoustics</i> , 2022, 26, 100355.	4.4	1
618	Screening for Hepatocellular Carcinoma in Viral Liver Disease: Is Ultrasound Enough?. , 0, , 9-12.		0
619	Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis. <i>Annals of Hepatology</i> , 2017, 16, 421-429.	0.6	5
620	Serum PPPICA as a Protein Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
621	Circulating cell-free DNA for cancer early detection. <i>Innovation(China)</i> , 2022, 3, 100259.	5.2	35
622	Interventional Radiology of the Liver. , 2015, , 1498-1519.		0
623	Comparison between using hepatocellular carcinoma ( <sc>HCC</sc> ) risk scores and the <sc>HCC</sc> national guideline to identify high-risk chronic hepatitis B patients for <sc>HCC</sc> surveillance in Thailand. <i>JGH Open</i> , 0, , .	0.7	2
624	Circulating MicroRNA Panel as a Diagnostic Marker for Hepatocellular Carcinoma. , 2022, 33, 844-851.		1
625	Ultrasonographic findings in patients with abdominal symptoms or trauma presenting to an emergency room in rural Tanzania. <i>PLoS ONE</i> , 2022, 17, e0269344.	1.1	1
626	Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 670-681.	8.2	106
627	A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. <i>Diagnostics</i> , 2022, 12, 1655.	1.3	5
628	Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1036-1048.	3.7	9
629	Incidentalomas are associated with an increase in liver transplantation in patients with cirrhosis: a single-center retrospective study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
631	Clinical value of contrast-enhanced ultrasound in early diagnosis of small hepatocellular carcinoma (â‰‰ 2 cm). <i>World Journal of Clinical Cases</i> , 2022, 10, 8525-8534.	0.3	1
632	Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 3917-3933.	1.4	6
633	Role of Ultrasound Methods for the Assessment of NAFLD. <i>Journal of Clinical Medicine</i> , 2022, 11, 4581.	1.0	12

#	ARTICLE	IF	CITATIONS
634	Proteome Multimarker Panel for the Early Detection of Hepatocellular Carcinoma: Multicenter Derivation, Validation, and Comparison. ACS Omega, 2022, 7, 29934-29943.	1.6	4
635	Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor. Journal of Controlled Release, 2022, 350, 11-25.	4.8	3
636	Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance. PLoS ONE, 2022, 17, e0274747.	1.1	1
637	Diagnosis and Evaluation of Hepatocellular Carcinoma. , 2022, , 27-48.		0
638	Detecting Early Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Using Longitudinal Î±-Fetoprotein Screening. Clinical Gastroenterology and Hepatology, 2023, 21, 1590-1597.	2.4	4
639	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease. Clinical and Molecular Hepatology, 2023, 29, S207-S219.	4.5	8
640	Physician- and patient-reported barriers to hepatocellular carcinoma surveillance: A nationwide survey. Medicine (United States), 2022, 101, e30538.	0.4	1
642	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 583-705.	4.5	102
643	Hepatocellular Carcinoma Recurrence: How to Manage. Updates in Surgery Series, 2023, , 191-197.	0.0	2
644	Surveillance for Patients at Risk of Developing Hepatocellular Carcinoma. Updates in Surgery Series, 2023, , 183-190.	0.0	0
645	LncRNA TCTN2 promotes malignant development of hepatocellular carcinoma via regulating miR-1285-3p/ARF6 Axis. Recent Patents on Anti-Cancer Drug Discovery, 2022, 18, .	0.8	0
646	Evaluation of HASTE T2 weighted image with reduced echo time for detecting focal liver lesions in patients at risk of developing hepatocellular carcinoma. European Journal of Radiology, 2022, 157, 110588.	1.2	4
647	Regularized Ultrasound Phantom-Free Local Attenuation Coefficient Slope (ACS) Imaging in Homogeneous and Heterogeneous Tissues. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2022, 69, 3338-3352.	1.7	4
648	Diagnosis and Management of Hepatocellular Carcinoma. In Clinical Practice, 2022, , 327-354.	0.1	0
649	Clinical big-data-based design of GLUT2-targeted carbon nanodots for accurate diagnosis of hepatocellular carcinoma. Nanoscale, 2022, 14, 17053-17064.	2.8	1
650	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean Journal of Radiology, 2022, 23, 1126.	1.5	44
651	Generating and Weighting Semantically Consistent Sample Pairs for Ultrasound Contrastive Learning. IEEE Transactions on Medical Imaging, 2023, 42, 1388-1400.	5.4	3
652	Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology Hepatology Coloproctology, 2022, 32, 104-140.	0.2	17

#	ARTICLE	IF	CITATIONS
653	A detailed strategy for hepatocellular carcinoma surveillance: the need of the hour. <i>Clinical and Molecular Hepatology</i> , 0, , .	4.5	0
654	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2023, 23, 1-120.	0.3	24
655	Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA. <i>Clinical Epigenetics</i> , 2023, 15, .	1.8	4
656	Evaluation of Ultrasound-based Surveillance for Hepatocellular Carcinoma in Patients at Risk: Results From a German Multicenter Retrospective Cohort Study. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	0
657	Metabolomics in hepatocellular carcinoma: From biomarker discovery to precision medicine. <i>Frontiers in Medical Technology</i> , 0, 4, .	1.3	10
658	Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2358.	1.8	5
659	Clinical significance of cylindromatosis expression in primary hepatocellular carcinoma. <i>Arab Journal of Gastroenterology</i> , 2023, , .	0.4	0
660	Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis. <i>Biomedicines</i> , 2023, 11, 382.	1.4	0
661	LABORATORY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA - CONVENTIONAL BIOMARKERS AND BLOOD PLASMA SPECTROSCOPY. <i>Military Medical Science Letters (Vojenske Zdravotnicke Listy)</i> , 2023, 92, 291-297.	0.2	0
662	The high burden of comorbidities in Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in Far North Queensland, Australia, and the implications for patient management. <i>PLoS ONE</i> , 2023, 18, e0284151.	1.1	3
663	Diagnostic accuracy of ultrasound and alpha-fetoprotein measurement for hepatocellular carcinoma surveillance: a retrospective comparative study. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2023, 54, .	0.3	4
664	Circulating DNA methylation profile improves the accuracy of serum biomarkers for the detection of nonmetastatic hepatocellular carcinoma. <i>Future Oncology</i> , 2022, 18, 4399-4413.	1.1	8
665	PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients. <i>Journal of Circulating Biomarkers</i> , 0, 12, 12-16.	0.8	0
666	EVALUATION OF DIAGNOSTIC VALIDITY OF PIVKA-II FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN PATIENTS OF CIRRHOSIS WITH LIVER NODULES PRESENTED IN A TERTIARY CARE HOSPITAL OF LAHORE. , 2023, 20, .		0
667	Screening of liver cancer with abbreviated MRI. <i>Hepatology</i> , 2023, 78, 670-686.	3.6	5
668	Imaging in Hepatocellular Carcinoma: What's New?. <i>Seminars in Ultrasound, CT and MRI</i> , 2023, 44, 145-161.	0.7	0
669	Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study. <i>Journal of Liver Cancer</i> , 2023, 23, 189-201.	0.3	2
670	A wide scan of plasma proteins demonstrates thioredoxin reductase 1 as a potential new diagnostic biomarker for hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2023, 58, 998-1008.	0.6	3

#	ARTICLE	IF	CITATIONS
678	Biomarkers for Hepatocellular Carcinoma in East Asia. <i>Biomarkers in Disease</i> , 2015, , 1-25.	0.0	0
698	Biomarker in Hepatocellular Carcinoma. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.3	0
701	Targeted Analysis of Glycerophospholipids and Mono-, Di-, or Tri-Acylglycerides in Liver Cancer. <i>Methods in Molecular Biology</i> , 2024, , 189-198.	0.4	0